1-2 of 2
Marie-Sophie Dheur, PhD PharmD
Close
Sort by
Journal Articles

First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Dries Deeren, MD PhD, Johan A. Maertens, MD PhD, Tara Lin, MD, Yves Beguin, MD PhD, Benjamin Demoulin, PhD, Martina Fontaine, PhD, Panagiota A. Sotiropoulou, PhD, Erik Alcantar-Orozco, MD, Eytan Breman, Marie-Sophie Dheur, PhD PharmD, Nathalie Braun, Caroline Lonez, PhD, David E Gilham, PhD, Anne Flament, MD, Frédéric F. Lehmann, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36.
https://doi.org/10.1182/blood-2020-139667
Published: 2020
Journal Articles

Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

David A. Sallman, MD, A. Samer Al-Homsi, MD, Marco L. Davila, MD PhD, Tessa Kerre, MD, Ine Moors, MD, Xavier Poire, MD, Violaine Havelange, MD, Philippe Lewalle, MD, Daniel A. Pollyea, Eunice S. Wang, MD, William Blum, MD, Benjamin Demoulin, PhD, Panagiota A. Sotiropoulou, PhD, Erik Alcantar-Orozco, MD, Eytan Breman, Marie-Sophie Dheur, PhD PharmD, Nathalie Braun, Caroline Lonez, PhD, David E Gilham, PhD, Anne Flament, MD, Frédéric F. Lehmann, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-139609
Published: 2020